ReproCELL Inc.

Company Snapshot

Founded: 2003
Entity Type: Public
Region: Japan
Headquarter: Kanagawa, Japan
Key Geographics: U.S., Europe, Asia-Pacific
Corporate Address: MetLife Shin-yokohama Bldg. 9F, 3-8-11 Shin-yokohama, Kohoku-ku, Yokohama, Kanagawa 222-0033, Japan Tel. +1-617-551-8200 www.reprocell.com

Company Overview

Established in 2003, ReproCELL Inc. is headquartered in Yokohama, Japan. Its group companies, BioServe (U.S.), Stemgent (U.S.), Reinnervate (U.K.), and Biopta (U.K.), serve as a single-source solution for reagents, services, and training across the entire regenerative medicine workflow. The company supplies reagents to support researchers in the derivation, maintenance, and differentiation of iPS cell lines. The company is able to procure primary patient samples from both normal and a diverse array of disease backgrounds.

Stemgent’s RNA reprogramming technology allows researchers to generate clinically compliant and integration-free iPSC lines from human blood and fibroblasts in their labs or through Stemgent’s service portal. In addition to research reagents for ES/iPS culture, the company offers iPSC-derived functional cells, including human cardiomyocytes, neurons, and hepatocytes, for use in endpoint assays, as well as disease model cells generated through iPSC technologies. ReproCELL claims to be the first company to commercialize iPSC-derived human cardiomyocytes, hepatocytes, and neuronal cells for research applications.

ReproCELL Inc. In Reports

Global Markets for Media, Sera and Reagents in Biotechnology

BCC Research Report: Dive into Media Sera and Reagents in Biotechnology market report considers 2023 as the base year and the forecast years 2024 through 2029.

Induced Pluripotent Stem Cells: Global Markets

BCC Research Market Analyst says global market for induced pluripotent stem cells is expected to grow from $3.4 billion in 2023 to reach $5.2 billion by the end of 2028 at a CAGR of 9.1% from 2023 to 2028.

Induced Pluripotent Stem Cells: Global Markets

BCC Research Market Report says global market for induced pluripotent stem cells is expected to grow from $3.4 billion in 2023 and forecast to reach $5.2 billion by the end of 2028 at a CAGR of 9.1%.

Company's Business Segments

  • Products : RNA Reprogramming, Small Molecules, Growth Factors and Cytokines, Antibodies and Staining Kits, Stem Cell Culture Media, Cell Substrates, Cryopreservation Media, Dissociation Solution, Transfection Reagents, Induced Pluripotent Stem Cells (iPSCs), Mesenchymal Stem Cells (MSCs), Differentiated iPSCs and Related Reagents, NeuCyte SynFire Induced Neurons, Feeder Cells, Alvetex 3D Cell Culture Systems, EZSPHERE Multiwell Dishes and Plates, KOKEN Atelocollagen (AteloCell), ABLE Biott Bioreactor Systems, Global Biorepository, Biospecimen Partner Network, Prospective Sample Collections, Primary Cell Derivation, Oligonucleotide Synthesis.
  • Services : Research Stem Cell Services, Clinical Stem Cell Services, StemEdit – Clinical Gene Editing, Precision Medicine, Preclinical and Drug Discovery CRO, Clinical Laboratory Services, Human Tissue Samples, Genomic Services.

Applications/End User Industries

  • Public Research Organizations e.g. Universities
  • Private Research Organizations e.g. Drug Manufacturers
  • Patients
  • Public and Private Hospitals